Journal List > Dement Neurocogn Disord > v.11(4) > 1120793

Dement Neurocogn Disord. 2012 Dec;11(4):131-135. Korean.
Published online Dec 31, 2012.
Copyright© 2012 Korean Dementia Association
A Clinical Significance of High-Sensitivity C-reactive Protein Level in Alzheimer's Disease and Vascular Dementia
Min-Jeong Wang, M.D., Eun-Ye Lim, M.D., Young-Do Kim, M.D., In-Uk Song, M.D., Sung-Woo Chung, M.D. and Young-Soon Yang, M.D.*
Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
*Department of Neurology, Veterans Hospital, Seoul Medical Center, Seoul, Korea.

Address for correspondence: In-Uk Song, M.D. Department of Neurology, Incheon St. Mary's Hospital, The Catholic University of Korea, 56 Dongsu-ro, Bupyeong-gu, Incheon 403-720, Korea. Tel: +82-32-280-5010, Fax: +82-32-280-5244, Email:
Received Oct 09, 2012; Revised Oct 09, 2012; Accepted Nov 12, 2012.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.



There is increasing evidence about inflammatory processes in the development of dementia. Therefore, inflammation has been believed to play a pivot role in cognitive decline, Alzheimer's disease (AD), and vascular dementia. High-sensitivity C-reactive protein (hs-CRP) is a sensitive systemic marker of inflammation, and increased levels of hs-CRP are associated with inflammatory reactions. It is important to identify modifiable risk factors, which could be used in preventing or delaying the onset of dementia. Therefore, we studied to clarify a clinical role of hs-CRP in AD and VaD.


This study population consisted of a sample of 102 patients with dementia (54 patients of AD and 48 patients of VaD) and 91 controls. We have investigated hs-CRP levels and cognitive function of each group. Cognitive function was evaluated with Mini-Mental State Examination (MMSE), Global Deterioration Scale (GDS), Clinical Dementia Rating (CDR) with Sum of Box and Activities of Daily Living (ADL).


All subjects with dementia showed higher hs-CRP levels than subjects without dementia. But, there was no significant difference of hs-CRP levels between patients with AD and those with VaD. The odds ratio of patients with AD and VaD by hs-CRP is 2.250 (95% Cl 1.670-3.032) for Alzheimer's disease and 4.0 (95% Cl 2.451-6.529) for vascular dementia.


The result of our study suggests the presence of inflammatory activity is related with dementia, not only AD known to degenerative disease but also VaD associated with cerebrovascular disease. However, we could suggest that dementia with cerebrovascular lesions is more related with inflammatory activity than AD.

Keywords: Inflammation; High-sensitivity C-reactive protein; Alzheimer's disease; Vascular dementia


Fig. 1
Mean hs-CRP value of patients with Alzheimer's disease (AD) and Vascular dementia (VaD) compared with normal controls. Mean hs-CRP value of AD and VaD patients are higher than normal controls (AD: 2.53±7.42, VaD: 1.39±1.77, Normal control: 0.074±0.06). The differences of hs-CRP value between AD and VaD patients are not significant statistically (p=0.768).
Click for larger image

Fig. 2
Odds Ratio and 95% confidence interval (CI) of patients with Alzheimer's disease (AD) and Vascular dementia (VaD) compared with normal controls for high-sensitivity C-reactive protein (hs-CRP). Values are expressed as odd ratio (95% CI). Rectangles indicate odds ratio and vertical lines represent 95% CIs.
Click for larger image


Table 1
Clinical characteristics of patients with dementia and without dementia
Click for larger image

Table 2
Relation between hs-CRP and variables in AD and VaD
Click for larger image

1. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141–1145.
2. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21:49–55.
3. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Athero-sclerosis apolipoprotein E, and prevalence of dementia and Alzheimers disease in the Rotterdam Study. Lancet 1997;349:151–154.
4. Ott A, Breteler MM, de Bruyne MC, van Harskamp FC, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a popula-tion-based study. The Rotterdam Study. Stroke 1997;28:316–321.
5. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995;45:1161–1168.
6. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and risk of dementia: the Rotterdam Study. Neurology 1999;53:1937–1942.
7. Gustafson D, Rotenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of over-weight and risk of Alzheimer disease. Arch Intern Med 2003;163:1524–1528.
8. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer's disease. Arch Neurol 2003;60:1707–1712.
9. Bassuk SS, Rifai N, Ridker PM. High sensitive C-reactive protein: clinical importance. Curr Probl Cardiol 2004;29:439–493.
10. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–1565.
11. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ 2000;321:199–204.
12. Praticó D, Trojanowski JQ. Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets? Neurobiol Aging 2000;21:441–445.
13. Breteler MBB. Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 2000;903:457–465.
14. Kuo HS, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005;4:371–380.
15. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging study. Ann Neurol 2002;52:168–174.
16. Ravaglia G, Forti P, Maioli F, Bastagli L, Chiappelli M, Montesi F, et al. Blood inflammatory markers and risk of dementia: the Conselice Study of brain aging. Neurobiol Aging 2007;28:1810–1820.
17. Nilsson K, Gustafson L, Hultberg B. The lack of association between plasma homocysteine and inflammation in psychogeriatric patients. Dement Geriatr Cogn Disord 2002;14:151–155.
18. Nilsson K, Gustafson L, Hultberg B. C-reactive protein: vascular risk marker in elderly patients with mental illness. Dement Geriatr Cogn Disord 2008;26:251–256.
19. Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growden JH, Hyman BT, et al. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 2008;65:776–778.
20. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32:2575–2579.
21. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003;61:76–80.
22. McGeer EG, Yasojima K, Schwab C, McGeer PL. The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol Aging 2001;22:843–848.
23. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 2004;6:261–266.
24. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004;363:1139–1146.
25. O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, et al. Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol 2010;23:49–53.
26. White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann NY Acad Sci 2002;977:9–23.
27. Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement 2009;5:318–323.
28. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383–421.